Two GREAT takeaways

1. Company said in its PR today:
"Given the serious nature of anti-TNF resistant RA, we believe that MPC-300-IV is well-positioned to be developed as a regenerative advanced therapy to target this major unmet medical need."

In about just over three months, the Phase 2 RA trial will be completed. Look for MSB pushing for accelerated approval after that, without the need for a Phase 3.

2. With such great results, Mesoblast continues to put three major pharma companies on notice.
Mesoblast's RA treatment bettered (in the initial 12 week result timeframe itself):
a) Humira, the highest grossing prescription drug on the planet, used primarily for RA
Humira is made by AbbVie, whose revenues are $23 billion USD, $14 billion of which are from Humira. AbbVie has a market cap of $110 billion USD
b) It also bettered Baricitinib, which recently finished Phase 3. Baricitinib is made by a partnership between Eli Lilly and  Incyte, whose combined market cap is $105 billion.
Baricitinib is a prescription drug to treat RA, which is touted to be better than Humira.

So Mesoblast RA treatment > Baricitinib > Humira
But wait!
This.   Is.   The.   Best.   Part:
A SINGLE MSB injection resulted in durable response through 9 months.
One and done for 9 months at a time? Seriously.
Compare that to daily doses with serious side effects from taking Humira and Baricitnib.
Let the fun begin.
@Rappa: Sorry couldn't resist your fave colors man.